Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease
Dan Hu,
Dong Hu,
Liwen Liu,
Daniel Barr,
Yang Liu,
Norma Balderrabano-Saucedo,
Bo Wang,
Feng Zhu,
Yumei Xue,
Shulin Wu,
BaoLiang Song,
Heather McManus,
Katherine Murphy,
Katherine Loes,
Arnon Adler,
Lorenzo Monserrat,
Charles Antzelevitch,
Michael H. Gollob,
Perry M. Elliott,
Hector Barajas-Martinez
Affiliations
Dan Hu
Department of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Corresponding author at: Department of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China.
Dong Hu
Center for Stem Cell Research and Application, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Liwen Liu
Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, China
Daniel Barr
Department of Chemistry, University of Mary, 7500 University Drive, Bismarck, ND, USA
Yang Liu
Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510080, China
Norma Balderrabano-Saucedo
Department of Cardiology, Children Hospital of Mexico Federico Gómez, México, D.F., México
Bo Wang
Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, China
Feng Zhu
Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Yumei Xue
Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510080, China
Shulin Wu
Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510080, China
BaoLiang Song
College of Life Sciences, Wuhan University, Wuhan, China
Heather McManus
Department of Chemistry and Biochemistry, Utica College, Utica, NY, USA
Katherine Murphy
Department of Chemistry, University of Mary, 7500 University Drive, Bismarck, ND, USA
Katherine Loes
Department of Chemistry, University of Mary, 7500 University Drive, Bismarck, ND, USA
Arnon Adler
Department of Physiology and the Peter Munk Cardiovascular Molecular Medicine Laboratory, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
Lorenzo Monserrat
Health in Code SL, A Coruña, Spain
Charles Antzelevitch
Lankenau Institute for Medical Research, Wynnewood, PA, USA; Lankenau Heart Institute, Sidney Kimmel College of Medicine, Thomas Jefferson University, USA
Michael H. Gollob
Department of Physiology and the Peter Munk Cardiovascular Molecular Medicine Laboratory, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
Perry M. Elliott
University College London and St. Bartholomew's Hospital, London, United Kingdom
Hector Barajas-Martinez
Lankenau Institute for Medical Research, Wynnewood, PA, USA; Lankenau Heart Institute, Sidney Kimmel College of Medicine, Thomas Jefferson University, USA
Background: Although 21 causative mutations have been associated with PRKAG2 syndrome, our understanding of the syndrome remains incomplete. The aim of this project is to further investigate its unique genetic background, clinical manifestations, and underlying structural changes. Methods: We recruited 885 hypertrophic cardiomyopathy (HCM) probands and their families internationally. Targeted next-generation sequencing of sudden cardiac death (SCD) genes was performed. The role of the identified variants was assessed using histological techniques and computational modeling. Findings: Twelve PRKAG2 syndrome kindreds harboring 5 distinct variants were identified. The clinical penetrance of 25 carriers was 100.0%. Twenty-two family members died of SCD or heart failure (HF). All probands developed bradycardia (HRmin, 36.3 ± 9.8 bpm) and cardiac conduction defects, and 33% had evidence of atrial fibrillation/paroxysmal supraventricular tachycardia (PSVT) and 67% had ventricular preexcitation, respectively. Some carriers presented with apical hypertrophy, hypertension, hyperlipidemia, and renal insufficiency. Histological study revealed reduced AMPK activity and major cardiac channels in the heart tissue with K485E mutation. Computational modelling suggests that K485E disrupts the salt bridge connecting the β and γ subunits of AMPK, R302Q/P decreases the binding affinity for ATP, T400N and H401D alter the orientation of H383 and R531 residues, thus altering nucleotide binding, and N488I and L341S lead to structural instability in the Bateman domain, which disrupts the intramolecular regulation. Interpretation: Including 4 families with 3 new mutations, we describe a cohort of 12 kindreds with PRKAG2 syndrome with novel pathogenic mechanisms by computational modelling. Severe clinical cardiac phenotypes may be developed, including HF, requiring close follow-up. Keywords: Genetics, Arrhythmia, PRKAG2 syndrome, Cardiomyopathy, Heart failure, Sudden cardiac death